173 related articles for article (PubMed ID: 33747421)
1. Concurrent application of blinatumomab and haploidentical donor leukocyte infusions for refractory primary mediastinal large B-cell lymphoma.
Smith J; Kumar A; Stanton NA; Katsanis E
Ther Adv Hematol; 2021; 12():2040620721994348. PubMed ID: 33747421
[TBL] [Abstract][Full Text] [Related]
2. Intentional induction of mixed chimerism and achievement of antitumor responses after nonmyeloablative conditioning therapy and HLA-matched donor bone marrow transplantation for refractory hematologic malignancies.
Spitzer TR; McAfee S; Sackstein R; Colby C; Toh HC; Multani P; Saidman S; Weyouth DW; Preffer F; Poliquin C; Foley A; Cox B; Andrews D; Sachs DH; Sykes M
Biol Blood Marrow Transplant; 2000; 6(3A):309-20. PubMed ID: 10905768
[TBL] [Abstract][Full Text] [Related]
3. Blinatumomab Redirects Donor Lymphocytes against CD19
Mancusi A; Zorutti F; Ruggeri L; Bonato S; Tricarico S; Zei T; Iacucci Ostini R; Viglione V; Sembenico R; Sciabolacci S; Cardinali V; Martelli MF; Mecucci C; Carotti A; Martelli MP; Velardi A; Pierini A
Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003295
[TBL] [Abstract][Full Text] [Related]
4. Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide/Bendamustine in Pediatric and Young Adult Patients with Hematologic Malignancies.
Katsanis E; Sapp LN; Varner N; Koza S; Stea B; Zeng Y
Biol Blood Marrow Transplant; 2018 Oct; 24(10):2034-2039. PubMed ID: 29908231
[TBL] [Abstract][Full Text] [Related]
5. Repeated CD45RA-depleted DLI successfully increases donor chimerism in a patient with beta-thalassemia major after haploidentical stem cell transplant.
Chan WYK; Kwok JSY; Chiang AKS; Chan GCF; Lee PPW; Ha SY; Cheuk DKL
Pediatr Transplant; 2021 Aug; 25(5):e13945. PubMed ID: 33314508
[TBL] [Abstract][Full Text] [Related]
6. HLA-haploidentical donor lymphocyte infusions for patients with relapsed hematologic malignancies after related HLA-haploidentical bone marrow transplantation.
Zeidan AM; Forde PM; Symons H; Chen A; Smith BD; Pratz K; Carraway H; Gladstone DE; Fuchs EJ; Luznik L; Jones RJ; Bolaños-Meade J
Biol Blood Marrow Transplant; 2014 Mar; 20(3):314-8. PubMed ID: 24296490
[TBL] [Abstract][Full Text] [Related]
7. Improved Outcome of Refractory/Relapsed Acute Myeloid Leukemia after Post-Transplantation Cyclophosphamide-Based Haploidentical Transplantation with Myeloablative Conditioning and Early Prophylactic Granulocyte Colony-Stimulating Factor-Mobilized Donor Lymphocyte Infusions.
Jaiswal SR; Zaman S; Chakrabarti A; Sen S; Mukherjee S; Bhargava S; Ray K; O'Donnell PV; Chakrabarti S
Biol Blood Marrow Transplant; 2016 Oct; 22(10):1867-1873. PubMed ID: 27470289
[TBL] [Abstract][Full Text] [Related]
8. Peritransplantation Glucocorticoid Haploidentical Stem Cell Transplantation Is a Promising Strategy for AML Patients With High Leukemic Burden: Comparison With Transplantations Using Other Donor Types.
Kaida K; Ikegame K; Inoue T; Maruyama S; Ishii S; Uchida N; Doki N; Eto T; Fukuda T; Katayama Y; Takada S; Kawakita T; Ichinohe T; Atsuta Y; Daimon T; Ogawa H
Transplant Cell Ther; 2023 Apr; 29(4):273.e1-273.e9. PubMed ID: 36641032
[TBL] [Abstract][Full Text] [Related]
9. Prophylactic Donor Lymphocyte Infusion (DLI) Followed by Minimal Residual Disease and Graft-versus-Host Disease-Guided Multiple DLIs Could Improve Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Refractory/Relapsed Acute Leukemia.
Yan CH; Liu QF; Wu DP; Zhang X; Xu LP; Zhang XH; Wang Y; Huang H; Bai H; Huang F; Ma X; Huang XJ
Biol Blood Marrow Transplant; 2017 Aug; 23(8):1311-1319. PubMed ID: 28483716
[TBL] [Abstract][Full Text] [Related]
10. Combination of Donor Lymphocyte Infusion and Blinatumomab for B-Cell Lymphoblastic Lymphoma Relapse after Allogeneic Stem-Cell Transplantation.
Mori J; Shingai N; Kobayashi T; Doki N
Case Rep Oncol; 2023; 16(1):640-644. PubMed ID: 37900800
[TBL] [Abstract][Full Text] [Related]
11. In relapsed patients after lymphocyte depleted bone marrow transplantation the percentage of donor T lymphocytes correlates well with the outcome of donor leukocyte infusion.
Schattenberg A; Schaap N; Van De Wiel-Van Kemenade E; Bär B; Preijers F; Van Der Maazen R; Roovers E; De Witte T
Leuk Lymphoma; 1999 Jan; 32(3-4):317-25. PubMed ID: 10037029
[TBL] [Abstract][Full Text] [Related]
12. T-cell--depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft-versus-myeloma effect.
Alyea E; Weller E; Schlossman R; Canning C; Webb I; Doss D; Mauch P; Marcus K; Fisher D; Freeman A; Parikh B; Gribben J; Soiffer R; Ritz J; Anderson K
Blood; 2001 Aug; 98(4):934-9. PubMed ID: 11493435
[TBL] [Abstract][Full Text] [Related]
13. T-Cell Replete Myeloablative Haploidentical Bone Marrow Transplantation Is an Effective Option for Pediatric and Young Adult Patients With High-Risk Hematologic Malignancies.
Katsanis E; Sapp LN; Reid SC; Reddivalla N; Stea B
Front Pediatr; 2020; 8():282. PubMed ID: 32582591
[TBL] [Abstract][Full Text] [Related]
14. Outcome of Haploidentical Peripheral Blood Allografts Using Post-Transplantation Cyclophosphamide Compared to Matched Sibling and Unrelated Donor Bone Marrow Allografts in Pediatric Patients with Hematologic Malignancies: A Single-Center Analysis.
Srinivasan A; Raffa E; Wall DA; Schechter T; Ali M; Chopra Y; Kung R; Chiang KY; Krueger J
Transplant Cell Ther; 2022 Mar; 28(3):158.e1-158.e9. PubMed ID: 34838785
[TBL] [Abstract][Full Text] [Related]
15. Combined Haploidentical and Umbilical Cord Blood Allogeneic Stem Cell Transplantation for High-Risk Lymphoma and Chronic Lymphoblastic Leukemia.
Hsu J; Artz A; Mayer SA; Guarner D; Bishop MR; Reich-Slotky R; Smith SM; Greenberg J; Kline J; Ferrante R; Phillips AA; Gergis U; Liu H; Stock W; Cushing M; Shore TB; van Besien K
Biol Blood Marrow Transplant; 2018 Feb; 24(2):359-365. PubMed ID: 29128555
[TBL] [Abstract][Full Text] [Related]
16. Early Fever after Haploidentical Bone Marrow Transplantation Correlates with Class II HLA-Mismatching and Myeloablation but Not Outcomes.
McCurdy SR; Muth ST; Tsai HL; Symons HJ; Huff CA; Matsui WH; Borrello I; Gladstone DE; Swinnen LJ; Cooke KR; Brodsky RA; Bolaños-Meade J; Ambinder RF; Varadhan R; Luznik L; Jones RJ; Bettinot MP; Fuchs EJ
Biol Blood Marrow Transplant; 2018 Oct; 24(10):2056-2064. PubMed ID: 29909152
[TBL] [Abstract][Full Text] [Related]
17. Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant.
Alyea EP; Soiffer RJ; Canning C; Neuberg D; Schlossman R; Pickett C; Collins H; Wang Y; Anderson KC; Ritz J
Blood; 1998 May; 91(10):3671-80. PubMed ID: 9573003
[TBL] [Abstract][Full Text] [Related]
18. HLA-Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide versus HLA-Matched Unrelated Donor Transplantation for Myelodysplastic Syndrome.
Nakaya Y; Koh H; Konuma T; Shimomura Y; Ishiyama K; Itonaga H; Hino M; Doki N; Nishida T; Ohigashi H; Matsuoka KI; Kanda Y; Maruyama Y; Sawa M; Eto T; Hiramoto N; Fukuda T; Atsuta Y; Nakamae H
Transplant Cell Ther; 2024 Mar; 30(3):316.e1-316.e12. PubMed ID: 38108263
[TBL] [Abstract][Full Text] [Related]
19. Impact of prophylactic donor leukocyte infusions on mixed chimerism, graft-versus-host disease, and antitumor response in patients with advanced hematologic malignancies treated with nonmyeloablative conditioning and allogeneic bone marrow transplantation.
Dey BR; McAfee S; Colby C; Sackstein R; Saidman S; Tarbell N; Sachs DH; Sykes M; Spitzer TR
Biol Blood Marrow Transplant; 2003 May; 9(5):320-9. PubMed ID: 12766882
[TBL] [Abstract][Full Text] [Related]
20. Leucyl-leucine methyl ester-treated haploidentical donor lymphocyte infusions can mediate graft-versus-leukemia activity with minimal graft-versus-host disease risk.
Hsieh MH; Varadi G; Flomenberg N; Korngold R
Biol Blood Marrow Transplant; 2002; 8(6):303-15. PubMed ID: 12108916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
